Hostname: page-component-78c5997874-fbnjt Total loading time: 0 Render date: 2024-11-03T08:39:13.238Z Has data issue: false hasContentIssue false
  • English
  • Français

177 Management of Treatment-Resistant Schizophrenia With Clozapine Augmentation

Published online by Cambridge University Press:  15 June 2018

Pwint Phyu ,
Emelina Arocha ,
Juan D. Oms ,
Luxhman Gunaseelan ,
Golbon Foroughi  and
Syed A. A. Rizvi
Pwint Phyu
Affiliation:
Post Graduate Year 3, Psychiatry Department, Larkin Community Hospital, Miami, FL
Emelina Arocha
Affiliation:
Attending Physician, Department of Psychiatry, Larkin Community Hospital, Miami, FL
Juan D. Oms
Affiliation:
Program Director, Department of Psychiatry, Larkin Community Hospital, Miami, FL
Luxhman Gunaseelan
Affiliation:
Saba University School of Medicine, Saba, Caribbean Netherlands
Golbon Foroughi
Affiliation:
Saba University School of Medicine, Saba, Caribbean Netherlands
Syed A. A. Rizvi
Affiliation:
Professor, Department of Pharmaceutical Sciences, College of Pharmacy, Nova Southeastern University, Fort Lauderdale, FL
Rights & Permissions [Opens in a new window]

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Abstract

A 44-year-old woman with a history of chronic schizoaffective disorder, epilepsy, social phobia, anxiety, and panic attacks presented with concern for “feeling anxious.” After a history, physical examination, and laboratory tests, the woman received a diagnosis of treatment-resistant schizophrenia. While clozapine is the standard therapy for schizophrenia, certain patients such as the woman in this case do not respond well to clozapine monotherapy, requiring clozapine to be augmented with other antipsychotics or antidepressants. This case outlines the unique challenges of managing patients with treatment-resistant schizophrenia, especially when they present with comorbid conditions such as epilepsy that can limit treatment options. A multipronged approach, including pharmacologic therapy as well as cognitive behavioral therapy, should also be considered.

Funding Acknowledgements

No funding.

Type
Abstracts
Information
CNS Spectrums , Volume 23 , Issue 1 , February 2018 , pp. 102
Copyright
© Cambridge University Press 2018